Global Nuclear Medicine Market Analysis and Forecast 2024-2030
Summary
Nuclear Medicine?or Radiopharmaceuticals? are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
According to APO Research, The global Nuclear Medicine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Nuclear Medicine include GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Nuclear Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Nuclear Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Medicine revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Nuclear Medicine revenue, projected growth trends, production technology, application and end-user industry.
Nuclear Medicine segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Nuclear Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Nuclear Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Medicine revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Nuclear Medicine?or Radiopharmaceuticals? are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
According to APO Research, The global Nuclear Medicine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Nuclear Medicine include GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Nuclear Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Nuclear Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Medicine revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Nuclear Medicine revenue, projected growth trends, production technology, application and end-user industry.
Nuclear Medicine segment by Company
- GE Healthcare
- Bracco Imaging
- Mallinckrodt
- Lantheus Medical Imaging
- Bayer
- Triad Isotopes
- Nordion
- Jubilant Pharma
- Eli Lilly
- SIEMENS
- China Isotope & Radiation
- Dongcheng
- Tc-99
- I-123/131
- In-111
- Xe-133
- Th-201
- Ga-67
- Others
- Diagnostic
- Therapeutic
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Nuclear Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Nuclear Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Medicine revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Nuclear Medicine Market by Type
1.2.1 Global Nuclear Medicine Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Tc-99
1.2.3 I-123/131
1.2.4 In-111
1.2.5 Xe-133
1.2.6 Th-201
1.2.7 Ga-67
1.2.8 Others
1.3 Nuclear Medicine Market by Application
1.3.1 Global Nuclear Medicine Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Diagnostic
1.3.3 Therapeutic
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 NUCLEAR MEDICINE MARKET DYNAMICS
2.1 Nuclear Medicine Industry Trends
2.2 Nuclear Medicine Industry Drivers
2.3 Nuclear Medicine Industry Opportunities and Challenges
2.4 Nuclear Medicine Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Nuclear Medicine Market Perspective (2019-2030)
3.2 Global Nuclear Medicine Growth Trends by Region
3.2.1 Global Nuclear Medicine Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Nuclear Medicine Market Size by Region (2019-2024)
3.2.3 Global Nuclear Medicine Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Nuclear Medicine Revenue by Players
4.1.1 Global Nuclear Medicine Revenue by Players (2019-2024)
4.1.2 Global Nuclear Medicine Revenue Market Share by Players (2019-2024)
4.1.3 Global Nuclear Medicine Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Nuclear Medicine Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Nuclear Medicine Key Players Headquarters & Area Served
4.4 Global Nuclear Medicine Players, Product Type & Application
4.5 Global Nuclear Medicine Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Nuclear Medicine Market CR5 and HHI
4.6.2 Global Top 5 and 10 Nuclear Medicine Players Market Share by Revenue in 2023
4.6.3 2023 Nuclear Medicine Tier 1, Tier 2, and Tier
5 NUCLEAR MEDICINE MARKET SIZE BY TYPE
5.1 Global Nuclear Medicine Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Nuclear Medicine Revenue by Type (2019-2030)
5.3 Global Nuclear Medicine Revenue Market Share by Type (2019-2030)
6 NUCLEAR MEDICINE MARKET SIZE BY APPLICATION
6.1 Global Nuclear Medicine Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Nuclear Medicine Revenue by Application (2019-2030)
6.3 Global Nuclear Medicine Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 GE Healthcare
7.1.1 GE Healthcare Comapny Information
7.1.2 GE Healthcare Business Overview
7.1.3 GE Healthcare Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.1.4 GE Healthcare Nuclear Medicine Product Portfolio
7.1.5 GE Healthcare Recent Developments
7.2 Bracco Imaging
7.2.1 Bracco Imaging Comapny Information
7.2.2 Bracco Imaging Business Overview
7.2.3 Bracco Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.2.4 Bracco Imaging Nuclear Medicine Product Portfolio
7.2.5 Bracco Imaging Recent Developments
7.3 Mallinckrodt
7.3.1 Mallinckrodt Comapny Information
7.3.2 Mallinckrodt Business Overview
7.3.3 Mallinckrodt Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.3.4 Mallinckrodt Nuclear Medicine Product Portfolio
7.3.5 Mallinckrodt Recent Developments
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Comapny Information
7.4.2 Lantheus Medical Imaging Business Overview
7.4.3 Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.4.4 Lantheus Medical Imaging Nuclear Medicine Product Portfolio
7.4.5 Lantheus Medical Imaging Recent Developments
7.5 Bayer
7.5.1 Bayer Comapny Information
7.5.2 Bayer Business Overview
7.5.3 Bayer Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.5.4 Bayer Nuclear Medicine Product Portfolio
7.5.5 Bayer Recent Developments
7.6 Triad Isotopes
7.6.1 Triad Isotopes Comapny Information
7.6.2 Triad Isotopes Business Overview
7.6.3 Triad Isotopes Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.6.4 Triad Isotopes Nuclear Medicine Product Portfolio
7.6.5 Triad Isotopes Recent Developments
7.7 Nordion
7.7.1 Nordion Comapny Information
7.7.2 Nordion Business Overview
7.7.3 Nordion Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.7.4 Nordion Nuclear Medicine Product Portfolio
7.7.5 Nordion Recent Developments
7.8 Jubilant Pharma
7.8.1 Jubilant Pharma Comapny Information
7.8.2 Jubilant Pharma Business Overview
7.8.3 Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.8.4 Jubilant Pharma Nuclear Medicine Product Portfolio
7.8.5 Jubilant Pharma Recent Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Comapny Information
7.9.2 Eli Lilly Business Overview
7.9.3 Eli Lilly Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.9.4 Eli Lilly Nuclear Medicine Product Portfolio
7.9.5 Eli Lilly Recent Developments
7.10 SIEMENS
7.10.1 SIEMENS Comapny Information
7.10.2 SIEMENS Business Overview
7.10.3 SIEMENS Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.10.4 SIEMENS Nuclear Medicine Product Portfolio
7.10.5 SIEMENS Recent Developments
7.11 China Isotope & Radiation
7.11.1 China Isotope & Radiation Comapny Information
7.11.2 China Isotope & Radiation Business Overview
7.11.3 China Isotope & Radiation Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.11.4 China Isotope & Radiation Nuclear Medicine Product Portfolio
7.11.5 China Isotope & Radiation Recent Developments
7.12 Dongcheng
7.12.1 Dongcheng Comapny Information
7.12.2 Dongcheng Business Overview
7.12.3 Dongcheng Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.12.4 Dongcheng Nuclear Medicine Product Portfolio
7.12.5 Dongcheng Recent Developments
8 NORTH AMERICA
8.1 North America Nuclear Medicine Revenue (2019-2030)
8.2 North America Nuclear Medicine Revenue by Type (2019-2030)
8.2.1 North America Nuclear Medicine Revenue by Type (2019-2024)
8.2.2 North America Nuclear Medicine Revenue by Type (2025-2030)
8.3 North America Nuclear Medicine Revenue Share by Type (2019-2030)
8.4 North America Nuclear Medicine Revenue by Application (2019-2030)
8.4.1 North America Nuclear Medicine Revenue by Application (2019-2024)
8.4.2 North America Nuclear Medicine Revenue by Application (2025-2030)
8.5 North America Nuclear Medicine Revenue Share by Application (2019-2030)
8.6 North America Nuclear Medicine Revenue by Country
8.6.1 North America Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Nuclear Medicine Revenue by Country (2019-2024)
8.6.3 North America Nuclear Medicine Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Nuclear Medicine Revenue (2019-2030)
9.2 Europe Nuclear Medicine Revenue by Type (2019-2030)
9.2.1 Europe Nuclear Medicine Revenue by Type (2019-2024)
9.2.2 Europe Nuclear Medicine Revenue by Type (2025-2030)
9.3 Europe Nuclear Medicine Revenue Share by Type (2019-2030)
9.4 Europe Nuclear Medicine Revenue by Application (2019-2030)
9.4.1 Europe Nuclear Medicine Revenue by Application (2019-2024)
9.4.2 Europe Nuclear Medicine Revenue by Application (2025-2030)
9.5 Europe Nuclear Medicine Revenue Share by Application (2019-2030)
9.6 Europe Nuclear Medicine Revenue by Country
9.6.1 Europe Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Nuclear Medicine Revenue by Country (2019-2024)
9.6.3 Europe Nuclear Medicine Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Nuclear Medicine Revenue (2019-2030)
10.2 China Nuclear Medicine Revenue by Type (2019-2030)
10.2.1 China Nuclear Medicine Revenue by Type (2019-2024)
10.2.2 China Nuclear Medicine Revenue by Type (2025-2030)
10.3 China Nuclear Medicine Revenue Share by Type (2019-2030)
10.4 China Nuclear Medicine Revenue by Application (2019-2030)
10.4.1 China Nuclear Medicine Revenue by Application (2019-2024)
10.4.2 China Nuclear Medicine Revenue by Application (2025-2030)
10.5 China Nuclear Medicine Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Nuclear Medicine Revenue (2019-2030)
11.2 Asia Nuclear Medicine Revenue by Type (2019-2030)
11.2.1 Asia Nuclear Medicine Revenue by Type (2019-2024)
11.2.2 Asia Nuclear Medicine Revenue by Type (2025-2030)
11.3 Asia Nuclear Medicine Revenue Share by Type (2019-2030)
11.4 Asia Nuclear Medicine Revenue by Application (2019-2030)
11.4.1 Asia Nuclear Medicine Revenue by Application (2019-2024)
11.4.2 Asia Nuclear Medicine Revenue by Application (2025-2030)
11.5 Asia Nuclear Medicine Revenue Share by Application (2019-2030)
11.6 Asia Nuclear Medicine Revenue by Country
11.6.1 Asia Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Nuclear Medicine Revenue by Country (2019-2024)
11.6.3 Asia Nuclear Medicine Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Nuclear Medicine Revenue (2019-2030)
12.2 MEALA Nuclear Medicine Revenue by Type (2019-2030)
12.2.1 MEALA Nuclear Medicine Revenue by Type (2019-2024)
12.2.2 MEALA Nuclear Medicine Revenue by Type (2025-2030)
12.3 MEALA Nuclear Medicine Revenue Share by Type (2019-2030)
12.4 MEALA Nuclear Medicine Revenue by Application (2019-2030)
12.4.1 MEALA Nuclear Medicine Revenue by Application (2019-2024)
12.4.2 MEALA Nuclear Medicine Revenue by Application (2025-2030)
12.5 MEALA Nuclear Medicine Revenue Share by Application (2019-2030)
12.6 MEALA Nuclear Medicine Revenue by Country
12.6.1 MEALA Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Nuclear Medicine Revenue by Country (2019-2024)
12.6.3 MEALA Nuclear Medicine Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Nuclear Medicine Market by Type
1.2.1 Global Nuclear Medicine Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Tc-99
1.2.3 I-123/131
1.2.4 In-111
1.2.5 Xe-133
1.2.6 Th-201
1.2.7 Ga-67
1.2.8 Others
1.3 Nuclear Medicine Market by Application
1.3.1 Global Nuclear Medicine Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Diagnostic
1.3.3 Therapeutic
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 NUCLEAR MEDICINE MARKET DYNAMICS
2.1 Nuclear Medicine Industry Trends
2.2 Nuclear Medicine Industry Drivers
2.3 Nuclear Medicine Industry Opportunities and Challenges
2.4 Nuclear Medicine Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Nuclear Medicine Market Perspective (2019-2030)
3.2 Global Nuclear Medicine Growth Trends by Region
3.2.1 Global Nuclear Medicine Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Nuclear Medicine Market Size by Region (2019-2024)
3.2.3 Global Nuclear Medicine Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Nuclear Medicine Revenue by Players
4.1.1 Global Nuclear Medicine Revenue by Players (2019-2024)
4.1.2 Global Nuclear Medicine Revenue Market Share by Players (2019-2024)
4.1.3 Global Nuclear Medicine Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Nuclear Medicine Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Nuclear Medicine Key Players Headquarters & Area Served
4.4 Global Nuclear Medicine Players, Product Type & Application
4.5 Global Nuclear Medicine Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Nuclear Medicine Market CR5 and HHI
4.6.2 Global Top 5 and 10 Nuclear Medicine Players Market Share by Revenue in 2023
4.6.3 2023 Nuclear Medicine Tier 1, Tier 2, and Tier
5 NUCLEAR MEDICINE MARKET SIZE BY TYPE
5.1 Global Nuclear Medicine Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Nuclear Medicine Revenue by Type (2019-2030)
5.3 Global Nuclear Medicine Revenue Market Share by Type (2019-2030)
6 NUCLEAR MEDICINE MARKET SIZE BY APPLICATION
6.1 Global Nuclear Medicine Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Nuclear Medicine Revenue by Application (2019-2030)
6.3 Global Nuclear Medicine Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 GE Healthcare
7.1.1 GE Healthcare Comapny Information
7.1.2 GE Healthcare Business Overview
7.1.3 GE Healthcare Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.1.4 GE Healthcare Nuclear Medicine Product Portfolio
7.1.5 GE Healthcare Recent Developments
7.2 Bracco Imaging
7.2.1 Bracco Imaging Comapny Information
7.2.2 Bracco Imaging Business Overview
7.2.3 Bracco Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.2.4 Bracco Imaging Nuclear Medicine Product Portfolio
7.2.5 Bracco Imaging Recent Developments
7.3 Mallinckrodt
7.3.1 Mallinckrodt Comapny Information
7.3.2 Mallinckrodt Business Overview
7.3.3 Mallinckrodt Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.3.4 Mallinckrodt Nuclear Medicine Product Portfolio
7.3.5 Mallinckrodt Recent Developments
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Comapny Information
7.4.2 Lantheus Medical Imaging Business Overview
7.4.3 Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.4.4 Lantheus Medical Imaging Nuclear Medicine Product Portfolio
7.4.5 Lantheus Medical Imaging Recent Developments
7.5 Bayer
7.5.1 Bayer Comapny Information
7.5.2 Bayer Business Overview
7.5.3 Bayer Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.5.4 Bayer Nuclear Medicine Product Portfolio
7.5.5 Bayer Recent Developments
7.6 Triad Isotopes
7.6.1 Triad Isotopes Comapny Information
7.6.2 Triad Isotopes Business Overview
7.6.3 Triad Isotopes Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.6.4 Triad Isotopes Nuclear Medicine Product Portfolio
7.6.5 Triad Isotopes Recent Developments
7.7 Nordion
7.7.1 Nordion Comapny Information
7.7.2 Nordion Business Overview
7.7.3 Nordion Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.7.4 Nordion Nuclear Medicine Product Portfolio
7.7.5 Nordion Recent Developments
7.8 Jubilant Pharma
7.8.1 Jubilant Pharma Comapny Information
7.8.2 Jubilant Pharma Business Overview
7.8.3 Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.8.4 Jubilant Pharma Nuclear Medicine Product Portfolio
7.8.5 Jubilant Pharma Recent Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Comapny Information
7.9.2 Eli Lilly Business Overview
7.9.3 Eli Lilly Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.9.4 Eli Lilly Nuclear Medicine Product Portfolio
7.9.5 Eli Lilly Recent Developments
7.10 SIEMENS
7.10.1 SIEMENS Comapny Information
7.10.2 SIEMENS Business Overview
7.10.3 SIEMENS Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.10.4 SIEMENS Nuclear Medicine Product Portfolio
7.10.5 SIEMENS Recent Developments
7.11 China Isotope & Radiation
7.11.1 China Isotope & Radiation Comapny Information
7.11.2 China Isotope & Radiation Business Overview
7.11.3 China Isotope & Radiation Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.11.4 China Isotope & Radiation Nuclear Medicine Product Portfolio
7.11.5 China Isotope & Radiation Recent Developments
7.12 Dongcheng
7.12.1 Dongcheng Comapny Information
7.12.2 Dongcheng Business Overview
7.12.3 Dongcheng Nuclear Medicine Revenue and Gross Margin (2019-2024)
7.12.4 Dongcheng Nuclear Medicine Product Portfolio
7.12.5 Dongcheng Recent Developments
8 NORTH AMERICA
8.1 North America Nuclear Medicine Revenue (2019-2030)
8.2 North America Nuclear Medicine Revenue by Type (2019-2030)
8.2.1 North America Nuclear Medicine Revenue by Type (2019-2024)
8.2.2 North America Nuclear Medicine Revenue by Type (2025-2030)
8.3 North America Nuclear Medicine Revenue Share by Type (2019-2030)
8.4 North America Nuclear Medicine Revenue by Application (2019-2030)
8.4.1 North America Nuclear Medicine Revenue by Application (2019-2024)
8.4.2 North America Nuclear Medicine Revenue by Application (2025-2030)
8.5 North America Nuclear Medicine Revenue Share by Application (2019-2030)
8.6 North America Nuclear Medicine Revenue by Country
8.6.1 North America Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Nuclear Medicine Revenue by Country (2019-2024)
8.6.3 North America Nuclear Medicine Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Nuclear Medicine Revenue (2019-2030)
9.2 Europe Nuclear Medicine Revenue by Type (2019-2030)
9.2.1 Europe Nuclear Medicine Revenue by Type (2019-2024)
9.2.2 Europe Nuclear Medicine Revenue by Type (2025-2030)
9.3 Europe Nuclear Medicine Revenue Share by Type (2019-2030)
9.4 Europe Nuclear Medicine Revenue by Application (2019-2030)
9.4.1 Europe Nuclear Medicine Revenue by Application (2019-2024)
9.4.2 Europe Nuclear Medicine Revenue by Application (2025-2030)
9.5 Europe Nuclear Medicine Revenue Share by Application (2019-2030)
9.6 Europe Nuclear Medicine Revenue by Country
9.6.1 Europe Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Nuclear Medicine Revenue by Country (2019-2024)
9.6.3 Europe Nuclear Medicine Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Nuclear Medicine Revenue (2019-2030)
10.2 China Nuclear Medicine Revenue by Type (2019-2030)
10.2.1 China Nuclear Medicine Revenue by Type (2019-2024)
10.2.2 China Nuclear Medicine Revenue by Type (2025-2030)
10.3 China Nuclear Medicine Revenue Share by Type (2019-2030)
10.4 China Nuclear Medicine Revenue by Application (2019-2030)
10.4.1 China Nuclear Medicine Revenue by Application (2019-2024)
10.4.2 China Nuclear Medicine Revenue by Application (2025-2030)
10.5 China Nuclear Medicine Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Nuclear Medicine Revenue (2019-2030)
11.2 Asia Nuclear Medicine Revenue by Type (2019-2030)
11.2.1 Asia Nuclear Medicine Revenue by Type (2019-2024)
11.2.2 Asia Nuclear Medicine Revenue by Type (2025-2030)
11.3 Asia Nuclear Medicine Revenue Share by Type (2019-2030)
11.4 Asia Nuclear Medicine Revenue by Application (2019-2030)
11.4.1 Asia Nuclear Medicine Revenue by Application (2019-2024)
11.4.2 Asia Nuclear Medicine Revenue by Application (2025-2030)
11.5 Asia Nuclear Medicine Revenue Share by Application (2019-2030)
11.6 Asia Nuclear Medicine Revenue by Country
11.6.1 Asia Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Nuclear Medicine Revenue by Country (2019-2024)
11.6.3 Asia Nuclear Medicine Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Nuclear Medicine Revenue (2019-2030)
12.2 MEALA Nuclear Medicine Revenue by Type (2019-2030)
12.2.1 MEALA Nuclear Medicine Revenue by Type (2019-2024)
12.2.2 MEALA Nuclear Medicine Revenue by Type (2025-2030)
12.3 MEALA Nuclear Medicine Revenue Share by Type (2019-2030)
12.4 MEALA Nuclear Medicine Revenue by Application (2019-2030)
12.4.1 MEALA Nuclear Medicine Revenue by Application (2019-2024)
12.4.2 MEALA Nuclear Medicine Revenue by Application (2025-2030)
12.5 MEALA Nuclear Medicine Revenue Share by Application (2019-2030)
12.6 MEALA Nuclear Medicine Revenue by Country
12.6.1 MEALA Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Nuclear Medicine Revenue by Country (2019-2024)
12.6.3 MEALA Nuclear Medicine Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Global Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Tc-99 Major Manufacturers
Table 2. I-123/131 Major Manufacturers
Table 3. In-111 Major Manufacturers
Table 4. Xe-133 Major Manufacturers
Table 5. Th-201 Major Manufacturers
Table 6. Ga-67 Major Manufacturers
Table 7. Others Major Manufacturers
Table 8. Global Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 9. Diagnostic Major Manufacturers
Table 10. Therapeutic Major Manufacturers
Table 11. Nuclear Medicine Industry Trends
Table 12. Nuclear Medicine Industry Drivers
Table 13. Nuclear Medicine Industry Opportunities and Challenges
Table 14. Nuclear Medicine Industry Restraints
Table 15. Global Nuclear Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 16. Global Nuclear Medicine Market Size by Region (2019-2024) & (US$ Million)
Table 17. Global Nuclear Medicine Market Share by Region (2019-2024)
Table 18. Global Nuclear Medicine Market Size by Region (2025-2030) & (US$ Million)
Table 19. Global Nuclear Medicine Market Share by Region (2025-2030)
Table 20. Global Nuclear Medicine Revenue by Players (US$ Million) & (2019-2024)
Table 21. Global Nuclear Medicine Revenue Market Share by Players (2019-2024)
Table 22. Global Nuclear Medicine Key Players Ranking, 2022 VS 2023 VS 2024
Table 23. Global Nuclear Medicine Key Players Headquarters & Area Served
Table 24. Global Nuclear Medicine Players, Product Type & Application
Table 25. Global Nuclear Medicine Players Commercialization Time
Table 26. Global Players Market Concentration Ratio (CR5 and HHI)
Table 27. Global Nuclear Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 28. Global Nuclear Medicine Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 30. Global Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Table 31. Global Nuclear Medicine Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 32. Global Nuclear Medicine Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 33. Global Nuclear Medicine Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Global Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 35. Global Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Table 36. Global Nuclear Medicine Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 37. Global Nuclear Medicine Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 38. GE Healthcare Company Information
Table 39. GE Healthcare Business Overview
Table 40. GE Healthcare Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 41. GE Healthcare Nuclear Medicine Product Portfolio
Table 42. GE Healthcare Recent Development
Table 43. Bracco Imaging Company Information
Table 44. Bracco Imaging Business Overview
Table 45. Bracco Imaging Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 46. Bracco Imaging Nuclear Medicine Product Portfolio
Table 47. Bracco Imaging Recent Development
Table 48. Mallinckrodt Company Information
Table 49. Mallinckrodt Business Overview
Table 50. Mallinckrodt Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 51. Mallinckrodt Nuclear Medicine Product Portfolio
Table 52. Mallinckrodt Recent Development
Table 53. Lantheus Medical Imaging Company Information
Table 54. Lantheus Medical Imaging Business Overview
Table 55. Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 56. Lantheus Medical Imaging Nuclear Medicine Product Portfolio
Table 57. Lantheus Medical Imaging Recent Development
Table 58. Bayer Company Information
Table 59. Bayer Business Overview
Table 60. Bayer Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 61. Bayer Nuclear Medicine Product Portfolio
Table 62. Bayer Recent Development
Table 63. Triad Isotopes Company Information
Table 64. Triad Isotopes Business Overview
Table 65. Triad Isotopes Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 66. Triad Isotopes Nuclear Medicine Product Portfolio
Table 67. Triad Isotopes Recent Development
Table 68. Nordion Company Information
Table 69. Nordion Business Overview
Table 70. Nordion Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 71. Nordion Nuclear Medicine Product Portfolio
Table 72. Nordion Recent Development
Table 73. Jubilant Pharma Company Information
Table 74. Jubilant Pharma Business Overview
Table 75. Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 76. Jubilant Pharma Nuclear Medicine Product Portfolio
Table 77. Jubilant Pharma Recent Development
Table 78. Eli Lilly Company Information
Table 79. Eli Lilly Business Overview
Table 80. Eli Lilly Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 81. Eli Lilly Nuclear Medicine Product Portfolio
Table 82. Eli Lilly Recent Development
Table 83. SIEMENS Company Information
Table 84. SIEMENS Business Overview
Table 85. SIEMENS Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 86. SIEMENS Nuclear Medicine Product Portfolio
Table 87. SIEMENS Recent Development
Table 88. China Isotope & Radiation Company Information
Table 89. China Isotope & Radiation Business Overview
Table 90. China Isotope & Radiation Nuclear Medicine Sales (M Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 91. China Isotope & Radiation Nuclear Medicine Product Portfolio
Table 92. China Isotope & Radiation Recent Development
Table 93. Dongcheng Company Information
Table 94. Dongcheng Business Overview
Table 95. Dongcheng Nuclear Medicine Sales (M Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 96. Dongcheng Nuclear Medicine Product Portfolio
Table 97. Dongcheng Recent Development
Table 98. North America Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 99. North America Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 100. North America Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 101. North America Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 102. North America Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 103. Europe Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 104. Europe Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 105. Europe Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. Europe Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 107. Europe Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 108. China Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 109. China Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 110. Asia Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 111. Asia Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 112. Asia Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 113. Asia Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 114. Asia Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 115. MEALA Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 116. MEALA Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 117. MEALA Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 118. MEALA Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 119. MEALA Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 120. Research Programs/Design for This Report
Table 121. Authors List of This Report
Table 122. Secondary Sources
Table 123. Primary Sources
Table 1. Global Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Tc-99 Major Manufacturers
Table 2. I-123/131 Major Manufacturers
Table 3. In-111 Major Manufacturers
Table 4. Xe-133 Major Manufacturers
Table 5. Th-201 Major Manufacturers
Table 6. Ga-67 Major Manufacturers
Table 7. Others Major Manufacturers
Table 8. Global Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 9. Diagnostic Major Manufacturers
Table 10. Therapeutic Major Manufacturers
Table 11. Nuclear Medicine Industry Trends
Table 12. Nuclear Medicine Industry Drivers
Table 13. Nuclear Medicine Industry Opportunities and Challenges
Table 14. Nuclear Medicine Industry Restraints
Table 15. Global Nuclear Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 16. Global Nuclear Medicine Market Size by Region (2019-2024) & (US$ Million)
Table 17. Global Nuclear Medicine Market Share by Region (2019-2024)
Table 18. Global Nuclear Medicine Market Size by Region (2025-2030) & (US$ Million)
Table 19. Global Nuclear Medicine Market Share by Region (2025-2030)
Table 20. Global Nuclear Medicine Revenue by Players (US$ Million) & (2019-2024)
Table 21. Global Nuclear Medicine Revenue Market Share by Players (2019-2024)
Table 22. Global Nuclear Medicine Key Players Ranking, 2022 VS 2023 VS 2024
Table 23. Global Nuclear Medicine Key Players Headquarters & Area Served
Table 24. Global Nuclear Medicine Players, Product Type & Application
Table 25. Global Nuclear Medicine Players Commercialization Time
Table 26. Global Players Market Concentration Ratio (CR5 and HHI)
Table 27. Global Nuclear Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 28. Global Nuclear Medicine Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 30. Global Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Table 31. Global Nuclear Medicine Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 32. Global Nuclear Medicine Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 33. Global Nuclear Medicine Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Global Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 35. Global Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Table 36. Global Nuclear Medicine Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 37. Global Nuclear Medicine Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 38. GE Healthcare Company Information
Table 39. GE Healthcare Business Overview
Table 40. GE Healthcare Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 41. GE Healthcare Nuclear Medicine Product Portfolio
Table 42. GE Healthcare Recent Development
Table 43. Bracco Imaging Company Information
Table 44. Bracco Imaging Business Overview
Table 45. Bracco Imaging Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 46. Bracco Imaging Nuclear Medicine Product Portfolio
Table 47. Bracco Imaging Recent Development
Table 48. Mallinckrodt Company Information
Table 49. Mallinckrodt Business Overview
Table 50. Mallinckrodt Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 51. Mallinckrodt Nuclear Medicine Product Portfolio
Table 52. Mallinckrodt Recent Development
Table 53. Lantheus Medical Imaging Company Information
Table 54. Lantheus Medical Imaging Business Overview
Table 55. Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 56. Lantheus Medical Imaging Nuclear Medicine Product Portfolio
Table 57. Lantheus Medical Imaging Recent Development
Table 58. Bayer Company Information
Table 59. Bayer Business Overview
Table 60. Bayer Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 61. Bayer Nuclear Medicine Product Portfolio
Table 62. Bayer Recent Development
Table 63. Triad Isotopes Company Information
Table 64. Triad Isotopes Business Overview
Table 65. Triad Isotopes Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 66. Triad Isotopes Nuclear Medicine Product Portfolio
Table 67. Triad Isotopes Recent Development
Table 68. Nordion Company Information
Table 69. Nordion Business Overview
Table 70. Nordion Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 71. Nordion Nuclear Medicine Product Portfolio
Table 72. Nordion Recent Development
Table 73. Jubilant Pharma Company Information
Table 74. Jubilant Pharma Business Overview
Table 75. Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 76. Jubilant Pharma Nuclear Medicine Product Portfolio
Table 77. Jubilant Pharma Recent Development
Table 78. Eli Lilly Company Information
Table 79. Eli Lilly Business Overview
Table 80. Eli Lilly Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 81. Eli Lilly Nuclear Medicine Product Portfolio
Table 82. Eli Lilly Recent Development
Table 83. SIEMENS Company Information
Table 84. SIEMENS Business Overview
Table 85. SIEMENS Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 86. SIEMENS Nuclear Medicine Product Portfolio
Table 87. SIEMENS Recent Development
Table 88. China Isotope & Radiation Company Information
Table 89. China Isotope & Radiation Business Overview
Table 90. China Isotope & Radiation Nuclear Medicine Sales (M Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 91. China Isotope & Radiation Nuclear Medicine Product Portfolio
Table 92. China Isotope & Radiation Recent Development
Table 93. Dongcheng Company Information
Table 94. Dongcheng Business Overview
Table 95. Dongcheng Nuclear Medicine Sales (M Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 96. Dongcheng Nuclear Medicine Product Portfolio
Table 97. Dongcheng Recent Development
Table 98. North America Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 99. North America Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 100. North America Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 101. North America Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 102. North America Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 103. Europe Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 104. Europe Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 105. Europe Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. Europe Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 107. Europe Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 108. China Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 109. China Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 110. Asia Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 111. Asia Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 112. Asia Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 113. Asia Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 114. Asia Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 115. MEALA Nuclear Medicine Revenue by Type (2019-2024) & (US$ Million)
Table 116. MEALA Nuclear Medicine Revenue by Application (2019-2024) & (US$ Million)
Table 117. MEALA Nuclear Medicine Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 118. MEALA Nuclear Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 119. MEALA Nuclear Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 120. Research Programs/Design for This Report
Table 121. Authors List of This Report
Table 122. Secondary Sources
Table 123. Primary Sources
LIST OF FIGURES
Figure 1. Nuclear Medicine Product Picture
Figure 2. Global Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Nuclear Medicine Market Size Share 2019 VS 2023 VS 2030
Figure 4. Tc-99 Picture
Figure 5. I-123/131 Picture
Figure 6. In-111 Picture
Figure 7. Xe-133 Picture
Figure 8. Th-201 Picture
Figure 9. Ga-67 Picture
Figure 10. Others Picture
Figure 11. Global Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Nuclear Medicine Market Size Share 2019 VS 2023 VS 2030
Figure 13. Diagnostic Picture
Figure 14. Therapeutic Picture
Figure 15. Global Nuclear Medicine Market Size (US$ Million) & (2019-2030)
Figure 16. Global Nuclear Medicine Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Nuclear Medicine Market Share by Region: 2019 VS 2023 VS 2030
Figure 18. Global Nuclear Medicine Players Revenue Share Top 10 and Top 5 in 2023
Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 20. Global Nuclear Medicine Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Nuclear Medicine Revenue Market Share 2019 VS 2023 VS 2030
Figure 22. Global Nuclear Medicine Revenue Market Share by Type (2019-2030)
Figure 23. Global Nuclear Medicine Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Nuclear Medicine Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 25. Global Nuclear Medicine Revenue Market Share by Application (2019-2030)
Figure 26. North America Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 28. North America Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 29. North America Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 30. North America Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 31. North America Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 32. United States Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 33. Canada Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 34. Europe Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 35. Europe Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 36. Europe Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 37. Europe Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 38. Europe Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 39. Europe Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 40. Germany Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. France Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. U.K. Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Italy Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Russia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Nordic Countries Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 46. China Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 47. China Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 48. China Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 49. China Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 50. China Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 51. Asia Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 52. Asia Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 53. Asia Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 54. Asia Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 55. Asia Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 56. Asia Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 57. Japan Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. South Korea Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. India Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Australia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. China Taiwan Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. Southeast Asia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 63. MEALA Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 64. MEALA Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 65. MEALA Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 66. MEALA Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 67. MEALA Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 68. MEALA Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 69. Mexico Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. South Korea Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Brazil Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Israel Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Argentina Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Colombia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Turkey Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Saudi Arabia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. UAE Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 78. Years Considered
Figure 79. Research Process
Figure 80. Key Executives Interviewed
Figure 1. Nuclear Medicine Product Picture
Figure 2. Global Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Nuclear Medicine Market Size Share 2019 VS 2023 VS 2030
Figure 4. Tc-99 Picture
Figure 5. I-123/131 Picture
Figure 6. In-111 Picture
Figure 7. Xe-133 Picture
Figure 8. Th-201 Picture
Figure 9. Ga-67 Picture
Figure 10. Others Picture
Figure 11. Global Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Nuclear Medicine Market Size Share 2019 VS 2023 VS 2030
Figure 13. Diagnostic Picture
Figure 14. Therapeutic Picture
Figure 15. Global Nuclear Medicine Market Size (US$ Million) & (2019-2030)
Figure 16. Global Nuclear Medicine Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Nuclear Medicine Market Share by Region: 2019 VS 2023 VS 2030
Figure 18. Global Nuclear Medicine Players Revenue Share Top 10 and Top 5 in 2023
Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 20. Global Nuclear Medicine Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Nuclear Medicine Revenue Market Share 2019 VS 2023 VS 2030
Figure 22. Global Nuclear Medicine Revenue Market Share by Type (2019-2030)
Figure 23. Global Nuclear Medicine Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Nuclear Medicine Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 25. Global Nuclear Medicine Revenue Market Share by Application (2019-2030)
Figure 26. North America Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 28. North America Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 29. North America Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 30. North America Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 31. North America Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 32. United States Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 33. Canada Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 34. Europe Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 35. Europe Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 36. Europe Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 37. Europe Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 38. Europe Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 39. Europe Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 40. Germany Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. France Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. U.K. Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Italy Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Russia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Nordic Countries Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 46. China Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 47. China Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 48. China Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 49. China Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 50. China Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 51. Asia Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 52. Asia Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 53. Asia Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 54. Asia Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 55. Asia Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 56. Asia Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 57. Japan Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. South Korea Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. India Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Australia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. China Taiwan Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. Southeast Asia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 63. MEALA Nuclear Medicine Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 64. MEALA Nuclear Medicine Revenue by Type (2025-2030) & (US$ Million)
Figure 65. MEALA Nuclear Medicine Revenue Share by Type (2019-2030)
Figure 66. MEALA Nuclear Medicine Revenue by Application (2025-2030) & (US$ Million)
Figure 67. MEALA Nuclear Medicine Revenue Share by Application (2019-2030)
Figure 68. MEALA Nuclear Medicine Revenue Share by Country (2019-2030)
Figure 69. Mexico Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. South Korea Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Brazil Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Israel Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Argentina Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Colombia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Turkey Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Saudi Arabia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. UAE Nuclear Medicine Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 78. Years Considered
Figure 79. Research Process
Figure 80. Key Executives Interviewed
